SPCS3

Across TCGA pan-cancer cohorts, SPCS3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SPCS3 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SPCS3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPCS3 expression acts as an unfavorable survival marker.

OV and MESO are the cancer types where SPCS3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.028	0.844	<.001	48	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SPCS3–OV (OS)

Open the OV breakdown →